Magnesio Solfato S.A.L.F. (Magnesium Sulfate Heptahydrate)

Magnesium sulfate releases magnesium ions that act as calcium antagonists, promote vasodilation, reduce neuromuscular excitability, and stabilize cardiac cell membranes. These actions help restore electrolyte balance, prevent abnormal electrical activity in the heart, and relax airway smooth muscle.

The appropriate dose of Magnesio Solfato S.A.L.F. is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical response. Dosing regimens are individualized and should follow local therapeutic guidelines.

Safety data for magnesium sulfate in pregnancy are limited, and the product is classified as pregnancy category unknown. Clinicians must weigh potential benefits against risks, and use it only when clearly indicated. Limited information is available regarding excretion in breast milk, so caution is advised.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Magnesio Solfato S.A.L.F. is a sterile injectable magnesium sulfate solution, offering rapid systemic availability compared with oral magnesium salts that have slower absorption. It is preferred in acute settings such as obstetric emergencies or life‑threatening arrhythmias, whereas oral formulations are used for chronic supplementation.

Store the injectable solution below 25 °C in its original packaging, protecting it from moisture and light. Do not freeze. Inspect the vial for particulate matter or discoloration before use, and follow aseptic techniques during preparation and administration.

The product is supplied as a sterile solution for intramuscular or intravenous injection. Administration route, infusion rate, and dilution are determined by the prescriber according to the clinical indication and patient condition. Monitoring of vital signs and serum magnesium levels is recommended during and after infusion.

Serious risks include severe hypotension, respiratory depression, cardiac arrest due to hypermagnesemia, and anaphylactic reactions. Patients with renal insufficiency, cardiac conduction disorders, or those receiving neuromuscular blockers are at higher risk and require close monitoring.

Magnesio Solfato S.A.L.F. is contraindicated in patients with known hypersensitivity to magnesium sulfate, severe renal failure where magnesium clearance is markedly reduced, and in individuals with existing hypermagnesemia. Caution is also advised for patients with myasthenia gravis or significant cardiac conduction abnormalities.